Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.49 |
| ▸ | DRD3 | P35462 | 5/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | ACHE | P22303 | 4/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13866811 | 1.00 | DRD2 (0.49) | DRD2DRD3OPRK1ESR2CYP19A1 | |
| SCHEMBL11224277 | 0.79 | DRD2 (0.41) | DRD2DRD3OPRK1ESR2CYP19A1 | |
| SCHEMBL11226905 | 0.79 | DRD2 (0.41) | DRD2DRD3OPRK1ESR2CYP19A1 | |
| SCHEMBL5071671 | 0.77 | PNMT (0.43) | — | |
| SCHEMBL13241439 | 0.77 | ACHE (0.44) | ACHE | |
| SCHEMBL13241438 | 0.77 | ACHE (0.44) | ACHE | |
| SCHEMBL4045125 | 0.77 | PSEN1 (0.42) | CA1CA2 | |
| SCHEMBL3033723 | 0.77 | ALDH1A1 (0.49) | CA1CA2 | |
| SCHEMBL3028797 | 0.77 | ALDH1A1 (0.49) | CA1CA2 | |
| SCHEMBL2485525 | 0.74 | IDO1 (0.44) | CYP19A1CA1CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667984-B1 | Gamma-secretase inhibitors | MERCK SHARP & DOHME (GB) | 2011-05-18 | — | — | EP | disclosed |
| EP-1560580-B1 | SULFONAMIDES, SULFAMATES AND SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME (GB) | 2011-01-12 | — | — | EP | disclosed |
| EP-1611129-B1 | CYCLIC SULFAMIDES FOR INHIBITION OF GAMMA-SECRETASE | MERCK SHARP & DOHME (GB) | 2009-09-30 | — | — | EP | disclosed |
| US-7514459-B2 | Gamma-secretase inhibitors | MERCK SHARP & DOHME LTD. (GB) | 2009-04-07 | — | — | US | disclosed |
| US-7427621-B2 | Cyclic sulfamides for inhibition of gamma-secretase | MERCK SHARP & DOHME LIMITED (GB) | 2008-09-23 | — | — | US | disclosed |
| US-7365196-B2 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK SHARP & DOHME LTD. (GB) | 2008-04-29 | — | — | US | disclosed |
| US-20080070895-A1 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | COLLINS IAN J | 2008-03-20 | — | — | US | disclosed |
| US-20060293373-A1 | Gamma-secretase inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2006-12-28 | — | — | US | disclosed |
| US-7144910-B2 | Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2006-12-05 | — | — | US | disclosed |
| EP-1268412-B1 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20060135570-A1 | Cyclic sulfamides for inhibiton of gamma-secretase | MERCK SHARP & DOHME LTD. (GB) | 2006-06-22 | — | — | US | disclosed |
| US-20060069147-A1 | Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME LTD. (GB) | 2006-03-30 | — | — | US | disclosed |
| US-20050143369-A1 | Gamma-secretase inhibitors | MERCK SHARP & DOHME LTD. (GB) | 2005-06-30 | — | — | US | disclosed |
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2004-03-11 | — | — | US | disclosed |
| US-20040029862-A1 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK CANADA INC. (CA) | 2004-02-12 | — | — | US | disclosed |
| US-4454325-A | ANALGESICS | MERCK SHARP & DOHME I.A. CORP. (US) | 1984-06-12 | — | — | US | disclosed |
| US-4376779-A | N-(Substituted)-2-aza-2'-hydroxy-5,6-benzotricyclo[6.3.01,8.04,11 ] undecane centrally-acting analgesics | MERCK SHARP & DOHME (I.A.) CORP. (US) | 1983-03-15 | — | — | US | disclosed |
| US-4341904-A | ANALGESICS; NARCOTICS ANTAGONIST | MERCK & CO., INC. (US) | 1982-07-27 | — | — | US | disclosed |
| US-4332807-A | NONADDICTIVE | MERCK & CO., INC. (US) | 1982-06-01 | — | — | US | disclosed |
| EP-0020885-A1 | Derivatives of 2-hydroxy-6,9-methano-11-amino-5,6,7,8,9,10-hexahydro-benzocyclooctene, process for their preparation and pharmaceutical compositions containing the same | MERCK SHARP & DOHME (I.A.) CORP. (US) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293373-A1 | Gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | DRD2 4838/4885DRD3 4803/4885OPRK1 3982/4885 |
| US-20060135570-A1 | Cyclic sulfamides for inhibiton of gamma-secretase | BACE1, PSEN1, BACE2 | DRD2 4648/4885DRD3 4720/4885OPRK1 3993/4885 |
| US-20060069147-A1 | Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors | BACE1, GSAP, BACE2 | DRD2 3849/4885DRD3 4016/4885OPRK1 3687/4885 |
| US-20080070895-A1 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | BACE1, BACE2, PSEN1 | DRD2 3487/4885DRD3 3406/4885OPRK1 2594/4885 |
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | DRD2 3495/4885DRD3 3789/4885OPRK1 3696/4885 |
| US-20040029862-A1 | Sulphonamido-substituted bridged bicycloalkyl derivatives | BACE1, BACE2, PSEN2 | DRD2 3508/4885DRD3 3339/4885OPRK1 3502/4885 |
| US-20050143369-A1 | Gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | DRD2 4790/4885DRD3 4759/4885OPRK1 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.